- Home
- WELL vs GILD Comparison
WELL vs GILD Comparison
Compare WELL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WELL | GILD |
|---|---|---|
| Founded | 1970 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.1B | 147.6B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | WELL | GILD |
|---|---|---|
| Price | $190.49 | $120.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $203.90 | $127.10 |
| AVG Volume (30 Days) | 3.6M | ★ 7.0M |
| Earning Date | 10-27-2025 | 10-30-2025 |
| Dividend Yield | 1.58% | ★ 2.62% |
| EPS Growth | N/A | ★ 6514.05 |
| EPS | 1.46 | ★ 6.42 |
| Revenue | $9,907,853,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $30.93 | $3.63 |
| Revenue Next Year | $17.66 | $2.97 |
| P/E Ratio | $127.98 | ★ $18.75 |
| Revenue Growth | ★ 32.28 | 2.79 |
| 52 Week Low | $123.11 | $88.57 |
| 52 Week High | $209.05 | $128.70 |
Technical Indicators
Market Signals| Indicator | WELL | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 44.95 |
| Support Level | $183.60 | $119.53 |
| Resistance Level | $205.55 | $123.74 |
| Average True Range (ATR) | 4.18 | 2.56 |
| MACD | -2.68 | -0.68 |
| Stochastic Oscillator | 26.84 | 18.01 |
Price Performance
Historical ComparisonAbout WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,391 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).